Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874519 · ClinicalTrials.gov registry record
Registry to Collect Health Information Related to Fibrolamellar Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 12
- Enrollment target
NCT04874519: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04874519 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04874519 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information about people with fibrolamellar cancer (FLC). This study is a registry of people with FLC around the world. This study will involve collecting information about participants, their medical history and the regular medical care they receive for FLC. The study will not provide treatment for your cancer.
Primary Outcome
To build a registry of Fibrolamellar Cancer/FLC through patient reported information, that could be studied further in future studies.
Interventions
- BEHAVIORAL Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-24 |
| Est. Completion | 2025-11-10 |
What the finished NCT04874519 record still lists
NCT04874519 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Questionnaire is the first listed.
NCT04874519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04874519 about?
NCT04874519 is a clinical study titled "Registry to Collect Health Information Related to Fibrolamellar Cancer". The purpose of this study is to collect information about people with fibrolamellar cancer (FLC). This study is a registry of people with FLC around the world. This study will involve collecting information about participants, their medical history and the regular medical care they receive for FLC. ...
What is the current status of trial NCT04874519?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2021-11-24. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT04874519?
The interventions under investigation include: Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT04874519?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI